Kiniksa Pharmaceuticals International (KNSA) Assets Average (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Assets Average came in at $860.7 million in Q2 2026, up 36.57% YoY from $630.2 million in Q2 2025, and up 8.34% on a QoQ basis from $794.5 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Assets Average (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 9 years of Assets Average data on file, last reported at $860.7 million in Q2 2026.
- Quarterly Assets Average rose 36.57% year-over-year to $860.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $860.7 million (up 36.57% YoY) and the FY2025 annual result came in at $672.1 million, up 21.44% from the prior year.
- Assets Average improved to $860.7 million in Q2 2026, from $794.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $860.7 million in Q2 2026 to a low of $220.8 million in Q2 2022.
- A 5-year average of $534.5 million and a median of $527.0 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average retreated 29.8% — and 2023, when it jumped 109.99%.
- Tracing KNSA's Assets Average over 5 years: stood at $459.8 million in 2022, then gained by 9.76% to $504.7 million in 2023, then grew by 12.53% to $567.9 million in 2024, then advanced by 29.94% to $738.0 million in 2025, then climbed by 16.63% to $860.7 million in 2026.
- The last three Assets Average figures came in at $860.7 million (Q2 2026), $794.5 million (Q1 2026), and $738.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 5.97 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.07 Bn | 5.54 Bn | 220.03 Mn | 860.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 860.70 Mn |
| Mar 31, 2026 | 794.46 Mn |
| Dec 31, 2025 | 737.98 Mn |
| Sep 30, 2025 | 686.74 Mn |
| Jun 30, 2025 | 630.24 Mn |
| Mar 31, 2025 | 589.94 Mn |
| Dec 31, 2024 | 567.93 Mn |
| Sep 30, 2024 | 548.86 Mn |
| Jun 30, 2024 | 531.05 Mn |
| Mar 31, 2024 | 523.00 Mn |
| Dec 31, 2023 | 504.69 Mn |
| Sep 30, 2023 | 483.70 Mn |
| Jun 30, 2023 | 463.60 Mn |
| Mar 31, 2023 | 451.27 Mn |
| Dec 31, 2022 | 459.81 Mn |
| Sep 30, 2022 | 335.26 Mn |
| Jun 30, 2022 | 220.77 Mn |
| Mar 31, 2022 | 231.88 Mn |
| Dec 31, 2021 | 242.83 Mn |
| Sep 30, 2021 | 266.03 Mn |